Oruka Therapeutics Announces Pricing of Upsized $700 Million Underwritten Public Offering
Rhea-AI Summary
Oruka Therapeutics (Nasdaq: ORKA) priced an upsized underwritten public offering of 9,660,000 common shares at $72.50 per share, expected to raise approximately $700.4 million in gross proceeds before underwriting discounts, commissions and offering expenses.
The company granted underwriters a 30‑day option to purchase up to an additional 1,449,000 shares. The offering is expected to close on or about April 30, 2026, subject to customary closing conditions. A shelf registration on Form S‑3 became effective on April 10, 2026.
Positive
- Gross proceeds of approximately $700.4 million before fees
- Offering was upsized to 9,660,000 shares
- Underwriters granted a 30‑day option for 1,449,000 additional shares
Negative
- Issuance of shares will dilute existing shareholders
- Net proceeds will be reduced by underwriting discounts, commissions and offering expenses
News Market Reaction – ORKA
In the Apr 29 session, ORKA declined 7.96%, reflecting a notable negative market reaction. Argus tracked a peak move of +6.9% during that session. Argus tracked a trough of -16.1% from its starting point during tracking. Our momentum scanner triggered 52 alerts that day, indicating high trading interest and price volatility. Trading volume was very high at 4.1x the daily average, suggesting heavy selling pressure.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 27 | Phase 2a data | Positive | +10.7% | Positive EVERLAST-A Week 16 ORKA-001 data with strong efficacy and safety. |
| Apr 26 | Conference call notice | Neutral | +10.7% | Announcement of webcast to present upcoming EVERLAST-A Week 16 data. |
| Mar 12 | Earnings and update | Positive | +25.0% | Q4/FY 2025 results with strong cash position and pipeline progress. |
| Feb 09 | Conference participation | Neutral | +0.6% | Planned participation in multiple investor and healthcare conferences. |
| Jan 12 | Clinical data update | Positive | +10.2% | Positive interim Phase 1 ORKA-002 data and EVERLAST-B initiation. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent ORKA news events, particularly clinical and earnings updates, have consistently coincided with positive single-day price reactions.
Over the last few months, Oruka has reported multiple positive clinical milestones for ORKA‑001 and ORKA‑002 and a supportive balance sheet. On Jan 12, 2026, favorable Phase 1 ORKA‑002 data and EVERLAST‑B initiation saw shares rise 10.16%. Q4 and full‑year 2025 results on Mar 12, 2026 highlighted $479.6 million in cash and drove a 25.04% move. Strong Phase 2a EVERLAST‑A data and related communications in late April produced double‑digit gains. Today’s offering follows this rally-driven backdrop.
Key Terms
underwritten public offering financial
shelf registration statement regulatory
form s-3 regulatory
prospectus supplement regulatory
prospectus regulatory
securities and exchange commission regulatory
lock-up period financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
MENLO PARK, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (Nasdaq: ORKA), a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis and other inflammatory and immunology indications, today announced the pricing of its upsized underwritten public offering of 9,660,000 shares of its common stock at a price to the public of
Leerink Partners, TD Cowen, Goldman Sachs & Co. LLC, Stifel and Guggenheim Securities are acting as joint bookrunning managers for the offering. LifeSci Capital is acting as passive bookrunning manager for the offering.
A shelf registration statement on Form S-3 (File No. 333-294852) relating to these securities has been filed with the Securities and Exchange Commission (the “SEC”) and became effective on April 10, 2026. This offering is being made solely by means of a prospectus supplement and accompanying prospectus. Oruka has filed a preliminary prospectus supplement and accompanying prospectus relating to and describing the terms of the offering with the SEC. A final prospectus supplement and accompanying prospectus relating to and describing the terms of the offering will also be filed with the SEC. These documents can be accessed for free through the SEC's website located at http://www.sec.gov. A copy of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained, when available, from: Leerink Partners LLC, Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, or by telephone at (800) 808-7525 ext. 6105, or by email at syndicate@leerink.com; TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at TDManualrequest@broadridge.com; Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at (866) 471-2526 or by email at prospectus-ny@ny.email.gs.com; Stifel, Nicolaus & Company, Incorporated, Attention: Prospectus Department, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at +1(415) 364-2720 or by email at syndprospectus@stifel.com; or Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@guggenheimpartners.com.
This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Oruka
Oruka Therapeutics is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka’s mission is to offer patients suffering from chronic skin diseases like plaque psoriasis the greatest possible freedom from their condition by achieving high rates of complete disease clearance with dosing as infrequently as once or twice per year. Oruka is advancing a proprietary portfolio of potentially best-in-class antibodies that were engineered by Paragon Therapeutics and target the core mechanisms underlying plaque psoriasis and other dermatologic and inflammatory diseases.
Forward-Looking Statements
Certain statements in this press release, other than purely historical information, may constitute “forward-looking statements” within the meaning of the federal securities laws, including for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995, concerning Oruka and other matters. These forward-looking statements include, but are not limited to, those relating to the completion of the offering and the expected amount and use of the net proceeds from the offering. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “potential,” “pipeline,” “can,” “target,” “believe,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “project,” “should,” “will,” “would” and similar expressions (including the negatives of these terms or variations of them) may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting Oruka will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Oruka’s control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, market conditions and the satisfaction of closing conditions, as well as those uncertainties and factors described under the heading “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in Oruka’s most recent Annual Report on Form 10-K for the year ended December 31, 2025, the preliminary prospectus supplement and accompanying prospectus relating to the offering and any subsequent filings with the SEC. Should one or more of these risks or uncertainties materialize, or should any of Oruka’s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth therein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Oruka does not undertake or accept any duty to make any updates or revisions to any forward-looking statements, except as required by applicable law. This press release does not purport to summarize all of the conditions, risks and other attributes of an investment in Oruka.
Investor Contact:
Alan Lada
(650) 606-7911
alan.lada@orukatx.com
